期刊文献+

罕见病药品的市场属性与管理特点 被引量:12

原文传递
导出
摘要 目的:了解罕见病药品特殊的市场性质与管理特点是解决罕见病药品供应问题的基础和关键。方法:比较分析罕见病药品与普通药品的市场特性和从研发到使用全过程中各市场主体的药事活动的特点与管理要求的差异性。结果:在罕用药供应的各阶段,市场主体都面临高成本和低利润的挑战,但如果设计好协调市场中各利益主体利益的动力机制和适应罕用药市场特性的管理新思路,投资罕用药的市场主体也会获得难得的发展机遇。结论:促进罕见病患者的用药可及性,增进社会和谐。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2009年第14期1221-1224,共4页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献17

  • 1龚时薇,张亮.我国罕用药研发呼唤政策支持[N].中国医药报,2007-04-26.
  • 2魏际刚.认清药品领域中政府和企业的责任——基于药品属性的分析[J].中国发展观察,2007(7):24-27. 被引量:5
  • 3龚时薇,张敏,邓秀玲,何惠君,李燕,王祎.对我国罕见病与罕用药界定的思考[J].中国新药杂志,2006,15(15):1225-1229. 被引量:20
  • 4冯立中,鲁先红.合肥罕见病患者求生困难[N].健康报,2007-02-08(2).
  • 5方剑春.生产不足,需求增长-血液制品供货紧张拉响警报[N].中国医药报,2007-07-26.
  • 6熊金超.武汉两家5口人铊中毒医院急寻救命药.新华网.2008.5.8.
  • 7Panos Kanavos. Providing Access to Modern Treatments and Influencing Policy in Orphan Diseases.. the International Experience and Evidence from the UK. LSE Health and Social Care [R]. 2005.
  • 8Michael F. Drummond, David A. Wilson, Panos Kanavos. Assessing the economic challenges posed by orphan drugs[J]. InternationalJournal of Technology Assessment in Health Care, 2007,23(1):36-42.
  • 9Marlene E Haffner. Adopting Orphan Drugs-Two Dozen Years of Treating Rare Diseases[J]. The New England Journal of Medicine. The New England Journal of Medicine. 2006, 354 (5) : 445-447.
  • 10Gericke C A, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development [J]. J Med Ethics, 2005, 31 : 164-168.

二级参考文献19

  • 1CAM YL.A Europe for People Living With Rare Diseases:Are we making the case?[C/OL].//Empowering the Rare Disease Community European Awareness Conference & Eurordis Meeting.Eurordis,Ireland(2004-06-26).http://www.eurordis.org/IMG/ppt/05_yann le cam.ppt.
  • 2HAFFNER ME.The current environment in orphan drug development[J].Drug Inf J,2003,37(4):373-379.
  • 3The Orphan Drug ACT:Implementation and Impact[R/OL]//USA Department of Health and Human services/Office of Inspector General (OEI-09-00-00380,5/01) (2004-10-21).http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf.
  • 4The orphan drug program and improving community access to effective drugs for rare diseases[R/OL]//Australia therapeutic goods administration (2004-08-31).http://www.tga.gov.au/docs/pdf/orphrev.pdf.html.
  • 5ROHDE DD.The orphan drug act:an engine of innovation? At what cost?[J].Food Drug Cosmet Law J,2000,55(1):125-143.
  • 6Despite incentives,regulatory barriers impede orphan drug development in Japan[EB/OL].(2003-03-12).http://www.ey.com/global/download.nsf/Denmark/LSN_March2003.pdf.
  • 7EMEA.Comp report to the commission in relation to article 10 of regulation 141/2000 on orphan orphan medicinal products[EB/OL].(2005-07-25).http://www.emea.eu.int/pdfs/human/comp/3521805 en.pdf.
  • 8FDA/OOPD.List of orphan designations and approvals[EB/OL].(2005-12-31).http://www.fda.gov/orphan/designat/list.htm.
  • 9ASHTON G.Growing pains for Biopharmacauticals[J].Nature Biotech,2001,19(4):307-311.
  • 10Mats Ericson, Christoper Webster, Francoise de Cremiers. Accelerated Assessment and Temporary Marketing Authorisation in the European Union [ J ]. RAJ pharma, 2004,9 : 645 - 6491

共引文献28

同被引文献112

引证文献12

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部